Q-omics provides the consensus-scored RPL17-C18orf32 profile across patient tissues and cancer cell-line models. RPL17-C18orf32 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPL17-C18orf32 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, RPL17-C18orf32 RNA expression shows 11,537 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUAD, and UVM as cancer lineages where RPL17-C18orf32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17-C18orf32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17-C18orf32 survival associations across molecular data types. RPL17-C18orf32 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17-C18orf32 RNA expression–survival associations across cancer types. High RPL17-C18orf32 expression shows unfavorable associations in HNSC, ACC, SKCM and KIRC, but favorable associations in BRCA and GBM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RPL17-C18orf32 RNA expression.
This table summarizes RPL17-C18orf32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17-C18orf32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17-C18orf32 shows lower tumor expression in LUAD, BRCA and KICH and higher tumor expression in KIRC, HNSC and ESCA. The LUAD box plot shows higher RPL17-C18orf32 RNA expression in normal versus tumor tissue (log2 FC = −0.095, t-test p = .010).
This table shows molecular features associated with RPL17-C18orf32 in patient tissues and cancer cell lines. In patient samples, RPL17-C18orf32 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL17-C18orf32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD.
